Cue Biopharma to Host Business Update Call and Webcast
The company will provide a clinical update from its ongoing Phase 1 trial evaluating CUE-101, the company’s lead interleukin 2 (IL-2)-based biologic from the CUE-100 series, in combination with pembrolizumab (KEYTRUDA®) for patients with recurrent/metastatic HPV+ head and neck cancer, as well as clinical progress from the Phase 1 monotherapy dose escalation trial of the company’s second clinical drug asset, CUE-102, for the treatment of patients with Wilms’ Tumor 1 (WT1)-positive recurrent/metastatic cancers. Additional clinical, pipeline and business updates will also be addressed.
Wednesday, August 9 at 4:30 p.m. EDT
|Request a return call via the Call me™ link:||https://emportal.ink/3KcjfmW|
|Participants can use the guest dial-in numbers above and be answered by an operator or click the Call me™ link for instant telephone access. The link will be active 15 minutes prior to the scheduled start time.|
About Cue Biopharma
Headquartered in Boston,
Senior Director, Corporate Communications
Source: Cue Biopharma, Inc.